India’s Revised Safety Norms are set to change how hospitals grow, with the Centre easing long-standing restrictions on building height. The Bureau of Indian Standards (BIS) has removed the 45-metre cap on hospital structures under the newly...
Aurobindo Pharma’s biosimilars arm CuraTeQ Biologics has secured a major regulatory milestone, as it wins Canada nod for its cancer biosimilar, marking a significant step in the company’s global expansion in oncology treatmen...
Bristol Myers beats quarterly profit estimates in its latest earnings report, driven by strong demand for its blood thinner and newer cancer treatments. The company posted adjusted earnings of USD 1.58 per share, topping analyst expectations...
The National Health Summit concluded today with a strong focus on Evidence-Based Health Reforms guided by findings from the 17th Common Review Mission (CRM) under the National Health Mission. The second day centered on technical discussions...
The Top Stories shaping the Pharma Industry right now show a clear shift—global deals, AI-led innovation, and policy clarity are driving momentum. From major acquisitions to breakthrough trials and public health moves, these updates reflect...
Zydus Lifesciences has expanded its presence in France healthcare market with a €700,000 acquisition of FBC Medical, a move that strengthens its position in the medical equipment distribution sector. The deal marks another step in the compan...
The Centre has relaxed CME rules, medtech firms, and UCMPMD code requirements, making it easier for companies to organise training and educational programmes for healthcare professionals. The revised policy aims to reduce approval delays whil...
India’s pharmaceutical sector is under renewed focus after Lilly supported Haryana’s crackdown on fake Mounjaro drug networks, following the seizure of counterfeit products in Gurugram. The action by the Haryana State Food and Drug Administra...
Abbott has announced a major leap in AI coronary imaging with regulatory clearances for its new Ultreon 3.0 platform. The system has received approval from the U.S. Food and Drug Administration and the CE Mark, signaling readiness for use in...
Pfizer Inc. has reported strong topline results from its phase 3 MagnetisMM-5 study, signaling a potential shift in myeloma treatment for patients with relapsed or refractory disease. The trial showed that Elrexfio significantly improved...
.jpg)
.jpg)
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")